logo
Adding to UnitedHealth woes, WSJ reports Justice Department has launched criminal investigation

Adding to UnitedHealth woes, WSJ reports Justice Department has launched criminal investigation

Miami Herald15-05-2025

UnitedHealth Group stock was sliding again Thursday as the market took in a report in the Wall Street Journal that the U.S. Department of Justice has launched a criminal fraud investigation of Medicare billing practices, the latest development in a string of allegations about the Eden Prairie-based company.
In a story posted late Wednesday, the Journal quoted sources familiar with the matter who said the investigation is overseen by the health care-fraud unit of the Justice Department's criminal division, and has been ongoing since at least last summer. Investigators are focusing on the company's business practices in Medicare Advantage health plans, although the exact nature of the allegations are unclear.
The Eden Prairie-based health care said in a statement to the Minnesota Star Tribune Wednesday night that it's not been notified by the Justice Department of any such investigation and called the story "deeply irresponsible."
"We stand by the integrity of our Medicare Advantage program," the health care company said.
UnitedHealth Group stock fell 14% in morning trading Thursday, marking the second major downward movement this week after the company abruptly announced Tuesday that CEO Andrew Witty was stepping down, to be immediately replaced as chief executive by Chairman Stephen Hemsley.
The news Wednesday followed reports earlier this year that the company's Medicare Advantage business was being investigated in a civil probe, after it had been singled out in a federal watchdog report for the questionable use of diagnosis data to boost payments from the government program for seniors by billions of dollars.
Allegations that insurers including UnitedHealthcare, the massive health insurance division at UnitedHealth, have gamed Medicare's risk-rating system in order to wrongly inflate their federal payments are not new. The company is still fighting a whistleblower lawsuit first filed in 2011 by an insider named Benjamin Poehling, who made similar allegations.
But investigative news reports over the past year, combined with widespread public anger at the company that was piqued following the killing of a top company executive on a public sidewalk in New York City, have contributed to the sense that UnitedHealth Group - a giant player in the nation's health care economy and the largest firm in Minnesota - has become a company under siege.
Hemsley put a brave face on the challenges in an internal message to employees earlier this week, which was obtained by the Minnesota Star Tribune.
"I am optimistic about our future since many of the issues standing in the way of achieving our goals are within our capacity to resolve," he wrote. "I know we will approach them with humility, rigor and urgency, guided as always by our mission to help people live healthier lives and help make the health system work better for everyone."
Medicare Advantage is a program in which the government pays private health insurers a per-member, per-month fee to provide medical benefits to seniors. These payments are increased based on "risk-adjustment" data submitted by insurers, so they are rewarded financially for managing care for people with serious health problems.
Historically, insurers faced criticism for shunning patients with high medical costs.
In early 2017, the federal government joined a whistleblower lawsuit from a former UnitedHealth Group employee in the Twin Cities who alleged, among other things, that the nation's largest insurer had wrongly received excess Medicare revenue by reviewing medical charts to boost payments without also making data corrections that would have saved the government money. The litigation was initially filed under seal by former employee Poehling in 2011.
In March, a court-appointed special master recommended the lawsuit not be allowed to move forward after finding no evidence to support key allegations about the company's alleged gaming risk-adjustment payments. The Justice Department in April said it wanted to push forward with the case, despite the special master's finding of a "complete failure" of evidence.
UnitedHealth Group stood out from its peers in an October 2024 federal watchdog report that questioned how Medicare Advantage insurers used diagnosis data to boost Medicare Advantage payments by billions of dollars.
The company was the biggest recipient of the add-on funds based on "questionable" practices for 2023, according to the report from the Office of the Inspector General (OIG) at the U.S. Department of Health and Human Services.
UnitedHealth Group insisted the OIG report was wrong. The watchdog agency published similar findings three years earlier, which UnitedHealth also rejected at the time as misleading and inaccurate.
OIG's reporting, plus coverage over the past year from the Wall Street Journal, prompted U.S. Sen. Chuck Grassley, R-Iowa, to demand answers from UnitedHealth Group on billing practices in a letter he sent in February.
Last July, the Wall Street Journal published an investigation that alleged UnitedHealthcare and other private insurers in Medicare Advantage made hundreds of thousands of questionable diagnoses that triggered an extra $50 billion in taxpayer-funded payments.
UnitedHealth Group pushed back against the newspaper's reporting that summer as well as a series of federal watchdog reports suggesting the company has stood out from others in its use of questionable practices to boost risk-adjustment payments in Medicare Advantage, the privatized version of the government health insurance program for seniors.
Then in February 2025, the Journal reported that the DOJ had initiated a separate civil fraud inquiry into UnitedHealth's Medicare billing practices. The company at the time insisted it was not aware of any such investigation.
"We are aware, however, that the Journal has engaged in a yearlong campaign to defend a legacy [Medicare] system that rewards volume over keeping patients healthy and addressing their underlying conditions," the company said at the time. "Any suggestion that our practices are fraudulent is outrageous and false."
In addition, UnitedHealth Group is confronting an unprecedented set of challenges.
Just this week, the company announced the return of longtime company leader Stephen Hemsley as chief executive, a move meant to restore confidence with investors amid a steep decline in the value of United shares. The stock has plunged with financial missteps under the leadership of former CEO Andrew Witty, who remains as a senior advisor.
Meanwhile, the company's reputation was significantly tarnished amid public outrage over health insurance industry practices following the killing of UnitedHealthcare CEO Brian Thompson. Ire has focused on the company due to its status as the nation's largest health insurer plus limited availability of data about claims denials, leaving it open to interpretation.
Lawsuits settled just in the past four months alleged the company's health insurance divisions weren't providing sufficient access to an emerging cancer treatment called proton beam radiation therapy as well as emergency room care and urinary drug screenings.
Other controversies include the continuing fallout from a massive cyberattack and withering criticism of the pharmacy benefit manager (PBM) industry where UnitedHealth is a major player. The Justice Department sued last year to block the company's proposed acquisition of Amedisys, a home care and hospice company.
In February 2024, UnitedHealth Group did not comment when the Wall Street Journal reported the Justice Department had opened an antitrust investigation of the company including interactions between the massive UnitedHealthcare health insurance and medical groups operated by United's Optum division for health care services.
And tough investigative reports over the past year or so from the Wall Street Journal and online health care news outlet STAT are among the exhibits cited by shareholders alleging securities fraud by the company in the U.S. District Court of Minnesota.
United has pushed back on all fronts.
On denials, the company insists it ultimately pays 98% of all claims received that are for eligible members, when submitted in a timely manner with complete, non-duplicate information. For the remainder that are not approved, the majority are instances where the services did not meet the benefit criteria established by the plan sponsor, UnitedHealth says, such as the employer, state or Centers for Medicare & Medicaid Services.
In the lawsuits over proton beam therapy and emergency room care, UnitedHealth denied the allegations and said it was reaching settlements to bring litigation to a close while admitting no wrongdoing. On the cyberattack, the company repeatedly has pointed to the billions in financial assistance it's provided to health care providers caught up in system shut down to contain damage from the hack.
Pharmacy benefits managers including UnitedHealth's Optum Rx division insist their tactics have been misconstrued and that critics don't appreciate how the companies provide a check on the power of drug companies to set high prices. And UnitedHealth has moved to dismiss the shareholder lawsuit, while contesting Justice Department claims in the Amedisys case.
Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Who would want to have babies under a Trump administration? Not me.
Who would want to have babies under a Trump administration? Not me.

USA Today

time21 minutes ago

  • USA Today

Who would want to have babies under a Trump administration? Not me.

Who would want to have babies under a Trump administration? Not me. | Opinion The Trump administration does not care about what is medically necessary to save someone's life. They care about controlling women. Why would anybody want to have a child under that way of thinking? Show Caption Hide Caption Trump rescinds Biden-era emergency abortion care guidance The Trump administration rescinded guidance clarifying that hospitals in abortion-ban states must treat pregnant patients during medical emergencies. unbranded - Newsworthy Despite declarations that something needs to be done about the declining birth rate in the United States, neither President Donald Trump nor the Republican Party has the desire to protect pregnant people. If they did, the Trump administration wouldn't have made its latest move to restrict abortion nationwide. On Tuesday, June 3, the Centers for Medicare and Medicaid Services rescinded a Biden-era policy that directed hospitals to provide emergency abortions if it was needed to stabilize a pregnant patient. The guidance and communications on it apparently 'do not reflect the policy of this Administration.' I, like many people who support abortion rights, know what this will lead to. It means more pregnant people will die. Does that reflect the policy of the administration? Having a baby in America is dangerous. Republicans aren't helping. The Biden policy was implemented in 2022, following the fall of Roe v. Wade, and argued that hospitals receiving Medicare funding had to comply with the Emergency Medical Treatment and Active Labor Act (EMTALA). The former administration argued that this included providing emergency abortions when they were needed to stabilize a patient, even in states that had severe abortion restrictions. Opinion: A brain dead pregnant Georgia woman is a horror story. It's Republicans' fault. This wasn't entirely a surprise. In 2024, the Supreme Court ruled that Texas could ban virtually all abortions in the state, including abortions that would have occurred under the old EMTALA guidelines. Still, it's terrifying to see this crucial policy eliminated. It's already dangerous to be pregnant in the United States. Our maternal mortality rate is much higher than in other wealthy countries. Same with our infant mortality rate. This will only exacerbate these tragedies. In states with abortion bans, the risks are even greater. A study from the Gender Equity Policy Institute found that people living in states with abortion bans were twice as likely to die during or shortly after childbirth. This is also backed by anecdotal evidence, including the 2022 deaths of two women in Georgia after the state passed a six-week ban. A different study found that infant mortality rates increased in states with severe restrictions on abortion, including an increase in deaths due to congenital anomalies. The Trump administration does not care about what is medically necessary to save someone's life. They don't care about whether the children supposedly saved by rescinding this policy will grow up without their mother. They care about their perceived moral superiority. They care about controlling women. Why would anybody want to have a child under that Republican way of thinking? Opinion: We're worrying about the wrong thing. Low birth rate isn't the crisis: Child care is. None of this is surprising from Republicans. It's just sad. I want to say I'm surprised that the Trump administration would allow women in need of emergency care to die. Yet this is clearly aligned with the Republican stance on abortion, just like it's aligned with the actions that the party has taken to make it harder for women to access necessary care. Whether you like it or not, abortion is a necessary part of health care. It saves lives. Alexis McGill Johnson, the president and CEO of Planned Parenthood, laid it out plainly. 'Women have died because they couldn't get the lifesaving abortion care they needed,' she said in a statement. 'The Trump administration is willing to let pregnant people die, and that is exactly what we can expect." Again, this is the administration that wants young women like me to have children and improve the country's birth rate. This is an administration that claims to care about women and children. I know I wouldn't want to have a child while Trump continues to make it unsafe to be pregnant and give birth. I hate that this is the reality. Follow USA TODAY columnist Sara Pequeño on X, formerly Twitter, @sara__pequeno

'Elon is going to get decimated:' How Trump's feud with the world's richest man might end
'Elon is going to get decimated:' How Trump's feud with the world's richest man might end

USA Today

time21 minutes ago

  • USA Today

'Elon is going to get decimated:' How Trump's feud with the world's richest man might end

'Elon is going to get decimated:' How Trump's feud with the world's richest man might end Show Caption Hide Caption President Trump gives his thoughts on Elon Musk amid clash on bill President Donald Trump responded to Elon Musk's criticism of his "big, beautiful bill" with disappointment as Musk responded on X. WASHINGTON — If history is any guide, and there is a lot of history, the explosive new falling out between President Donald Trump and Elon Musk is not going to end well for the former White House advisor and world's richest man. The political battlefield is littered with the scorched remains of some of Trump's previous allies who picked a fight with him or were on the receiving end of one. Lawyer Michael Cohen. Political advisor Steve Bannon. Attorney General Jeff Sessions, Defense Secretary James Mattis and Secretary of State Rex Tillerson. John Bolton, John Kelly and Chris Christie, to name just a few. 'If what happened to me is any indication of how they handle these matters, then Elon is going to get decimated,' said Cohen, the former long-term Trump lawyer and fixer who once said he'd 'take a bullet' for his boss. Musk, he said, "just doesn't understand how to fight this type of political guerilla warfare." 'They're going to take his money, they're going to shutter his businesses and they're going to either incarcerate or deport him,' Cohen said of what he thinks Musk will suffer at the hands of Trump and his administration. 'He's probably got the White House working overtime already, as we speak, figuring out how to close his whole damn thing down.' Cohen had perhaps the most spectacular blow up, until now, with Trump. He served time in prison after Trump threw him under the bus by denying any knowledge of pre-election payments Cohen made to a porn actress to keep her alleged tryst with Trump quiet before the 2016 election. More: President Trump threatens Elon Musk's billions in government contracts as alliance craters Cohen felt so betrayed by Trump that he titled his memoir 'Disloyal,' but the Trump administration tried to block its publication. Cohen ultimately fought back, becoming a star witness for the government in the state 'hush money' case and helped get Trump convicted by a Manhattan jury. Some suffered similar legal attacks and other slings and arrows, including Trump taunts and his trademark nasty nicknames. Trump vilified others, casting them into the political wilderness with his MAGA base. When Sessions recused himself from the Justice Department's investigation of Russian meddling in the 2016 election, Trump savaged him, calling his appointment a 'mistake' and lobbing other epithets. Sessions resigned under pressure in 2018. When he tried to resurrect his political career by running for his old Senate seat in Alabama, Trump endorsed his opponent, who won the GOP primary. After firing Tillerson, Trump called the former ExxonMobil chief lazy and 'dumb as a rock.' Trump still taunts Christie, an early supporter and 2016 transition chief, especially about his weight. Trump also had a falling out with Bannon, who was instrumental in delivering his presidential victory in 2016 and then joined the White House as special advisor. 'Steve Bannon has nothing to do with me or my Presidency,' Trump said in 2018, a year after Bannon's ouster from the White House. 'When he was fired, he not only lost his job, he lost his mind.' Trump's Justice Department even indicted Bannon in 2020 for fraud, though the President pardoned him before leaving office. One of Trump's biggest feuds was with Bolton, whom he fired as his national security advisor in 2019. Trump used every means possible to prevent his book, 'The Room Where it Happened,' from being published, Bolton told USA TODAY on Thursday. That included having the U.S. government sue his publisher on the false premise that Bolton violated a nondisclosure agreement and was leaking classified information, Bolton said. Bolton said Musk is unlike most others who have crossed swords with Trump in that he has unlimited amounts of money and control of a powerful social media platform in X to help shape the narrative. Musk also has billions in government contracts that even a vindictive Trump will have a hard time killing, as he threatened to do on Thursday, without significant legal challenges. Even so, Bolton said, "It's going to end up like most mud fights do, with both of them worse off. The question is how much worse the country is going to be off."

Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment

Yahoo

time22 minutes ago

  • Yahoo

Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment

Discover the future of the Molecular Diagnostics - Infectious Disease sector with our comprehensive report. Explore how multiplex assays and rapid testing are transforming diagnosis and treatment amidst the boom in biotechnology and genomics. This detailed analysis covers dynamic trends such as pathogen evolution, globalization, and climate change impacts. Benefit from extensive insights, including U.S. Medicare Fee Schedules, and detailed global data. Equip your organization with expert knowledge today. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" report has been added to offering. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report - and find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. The report includes detailed breakouts for 15 countries and 4 regions. A detailed breakout for any country in the world is available to purchasers of the report. This research makes you the expert in your organization. Assistance and additional specific data is provided without additional charges. All report data is available in Excel format on request. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides1.1 Situation Analysis2 Introduction and Market Definition2.1 Market Definition2.1.1 Market Size2.1.2 Currency2.1.3 Years2.2 Methodology2.2.1 Methodology2.2.2 Sources2.2.3 Authors2.3 Perspective: Healthcare Spending2.3.1 Global Healthcare Spending2.3.2 Spending on Healthcare and Pharmaceuticals2.3.3 Spending on Diagnostics2.3.4 Important Role of Insurance for Medical Services2.4 The Nature of the IVD Product2.4.1 Features Overview2.4.2 The Misunderstood Feature2.4.3 Regulation2.4.4 The Newest Feature2.4.5 The Oldest Feature2.4.6 All About Scope2.4.7 Why Turnaround is Becoming More Important2.4.8 The Role of Trust2.5 The IVD Product of the Future3 Infectious Diseases - Guide to the Pathogens3.1 Infectious Disease Pathogens - The Big Picture3.1.1 Viruses3.1.2 Bacteria3.1.3 Fungi3.1.4 Parasites3.1.5 Prions3.1.6 Virulence3.1.7 Transmission3.2 The Coronavirus3.2.1 Severe acute respiratory syndrome (SARS)3.2.2 Middle East respiratory syndrome (MERS)3.2.3 COVID-19. The SARS CoV 2 Virus3.2.3.1 Signs and symptoms3.2.3.2 Transmission3.2.3.3 Diagnosis3.2.3.4 Prevention3.2.3.5 Management3.2.3.6 Prognosis4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.2.3 Segmenting the Syndromic Testing Market4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.3 Hospital vs. Central Lab4.3.4 Physician Office Lab's4.3.5 Physician's and POCT5 Market Trends5.1 Factors Driving Growth5.1.1 The Nucleic Acid Impact5.1.2 Population Dynamics5.1.3 The Developing World5.1.4 Decentralization5.1.5 Self Testing5.1.6 The Need for Speed5.2 Factors Limiting Growth5.2.1 Costs and Experience Curve Effects5.2.2 The Role of ID Prevalence5.2.3 Wellness5.2.4 The Impact of Living Standards5.3 Instrumentation, Automation and Diagnostic Trends5.3.1 Traditional Automation and Centralization5.3.2 The New Automation, Decentralization and Point of Care5.3.3 Instruments Key to Market Share5.3.4 Bioinformatics Plays a Role5.3.5 PCR Takes Command5.3.6 Next Generation Sequencing Fuels a Revolution5.3.7 NGS Impact on Pricing5.3.8 Whole Genome Sequencing, A Brave New World5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment6 Clinical Laboratory MDx Infectious Disease Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Presymptom Health Nabs Funding for Sepsis Test6.3 FDA Clears BioMerieux GI Panel6.4 Rapid Infection Diagnostic Launches BSIDx6.5 Biotia's AI-, Sequencing-Based UTI Test approved6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic6.7 Roche Respiratory Panel Receives FDA EUA6.8 Genetic Signatures Gets Approval for GI Parasite Panel6.9 Diasorin Expands Respiratory Panel6.10 BioMerieux Outlines MDx-Driven Growth6.11 T2 Biosystems Gets Extended T2Bacteria Panel6.12 Diasorin Aims to Deliver Updated Instruments, New Assays6.13 Oxford Nanopore Nabs Investment From BioMerieux6.14 Day Zero Diagnostics Closes Financing Round6.15 Spindiag Seeks Investors for Rapid PCR System6.16 Sorrento Therapeutics Nabs Contract for Dx Platform6.17 Kephera Planning Menu of Infectious Disease Tests6.18 Oxford Nanopore and BioMerieux to Develop IDDx6.19 SD Biosensor Eyes Global Expansion6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance6.21 Takara Developing High-Throughput Multiplex Panels6.22 BioGX Debuts New Point-of-Care Molecular Testing System6.23 Nanopath MDx Platform Providing 15-Minute Results6.24 ProtonDx Commercializing Rapid MDx Instrument6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS6.27 Accelerate Diagnostics Anticipates Growth6.28 Lumos Diagnostics Expanding Test Portfolio6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens7 Key Companies7.1 Abbott Laboratories7.2 Agilent7.3 Altona Diagnostics7.4 Anitoa7.5 Autonomous Medical Devices7.6 Beckman Coulter Diagnostics (Danaher)7.7 Becton, Dickinson and Company7.8 BioGX7.9 Biomatik7.10 bioMerieux Diagnostics7.11 Bio-Rad Laboratories, Inc.7.12 Cepheid (Danaher)7.13 Diasorin S.p.A.7.14 DNAe7.15 Flow Health7.16 Global Access Diagnostics7.17 Great Basin Scientific, Inc.7.18 Hologic7.19 Novacyt7.20 Novus Diagnostics7.21 Oncimmune7.22 One Codex7.23 OraSure Technologies7.24 Prometheus Laboratories7.25 Qiagen7.26 QuidelOrtho7.27 R-Biopharm AG7.28 Response Biomedical7.29 Revvity7.30 Roche Diagnostics7.31 Siemens Healthineers7.32 Thermo Fisher Scientific7.33 Vela Diagnostics7.34 Veredus Laboratories7.35 YD Diagnostics7.36 Zhejiang Orient Gene Biotech8 The Global Market for Clinical Laboratory MDx Infectious Disease8.1 Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Place - Overview9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application9.1 Respiratory9.2 Blood Borne Virus9.3 Transplant9.4 Hospital Acquired Infections9.5 Reproductive Health9.6 C19 Singleplex9.7 Meningitis9.8 Gastrointestinal9.9 Tropical10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place10.1 Hospital Lab10.2 Outpatient Lab10.3 Point of Care10.4 Other Place11 Appendices11.1 Growth of Approved IVD Test Menu11.2 Growth of Approved Average IVD Test Fee11.3 The Most Used IVD Assays11.4 The Highest Grossing Assays11.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store